ASSENT-4 PCI研究课件.ppt

The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial: Mortality at 30 days ASSENT- 4 PCI Trial: Mortality Subgroup Analysis ASSENT- 4 PCI Trial: Total Stroke and ICH at 30 days ASSENT- 4 PCI Trial: Ischemic Stroke, Haemorrhagic Conversion, and Unclassified Stroke Rates at 30 days ASSENT- 4 PCI Trial: Bleeding Events at 30 days ASSENT- 4 PCI Trial: Transfusions at 30 days ASSENT- 4 PCI Trial: Comparison with Previous ASSENT Trials (TNK in MI patients) ASSENT- 4 PCI Trial: Comparison with Previous ASSENT Trials (TNK in MI patients) ASSENT- 4 PCI Trial: Comparison with Previous ASSENT Trials (TNK in MI patients) ASSENT- 4 PCI Trial: Comparison with Previous ASSENT Trials (TNK in MI patients) ASSENT- 4 PCI Trial: Comparison with Previous ASSENT Trials (TNK in MI patients) ASSENT- 4 PCI Trial: Comparison with Those in Primary-PCI Overview ASSENT- 4 PCI Trial: Comparison with Those in Primary-PCI Overview ASSENT- 4 PCI Trial: Comparison with Those in Primary-PCI Overview ASSENT- 4 PCI Trial: Comparison with Those in Primary-PCI Overview ASSENT- 4 PCI Trial: Comparison with Those in Primary-PCI Overview ASSENT- 4 PCI Trial: Summary The trial intended to enroll 4,000 patients, but was discontinued early after enrollment of 1,667 patients. Among patients with ST elevation MI intended for primary PCI, administration of full-dose fibrinolytic (TNK) immediately prior to PCI was associated with increased mortality and stroke at 30 days compared with primary PCI alone. Primary endpoint data are not yet available. Further evaluation of the clinical benefit of fibrinolytics among patients undergoing early PCI for STEMI appears warranted (FINESSE). www. Clinical trial ASSENT- 4 PCI Trial Presented at The European Society of Cardiology Hot Line Session 2005 Presented by Dr. Frans Van de Werf Full-dose TNK + Primary PCI 60 IU/kg, maximum 4000 IU n=829 GP IIb/IIIa inhibitors allowed only fo